GlassScriptPhysician profile
Andrew John Lepinski
NPI 1902829989
$4,085.56
in general payments reported to CMS, 2019-2025
47 companies · $743 in 2025
The $743 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $301 · 2021: $524 · 2022: $849 · 2023: $447 · 2024: $393 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,583.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $509.43 | 2019-2025 | Veozah, Myrbetriq, Xtandi |
| Abbvie INC. | $494.51 | 2019-2025 | |
| Pfizer INC. | $234.99 | 2019-2025 | |
| Janssen Biotech, INC. | $218.75 | 2019-2025 | Erleada, Akeega |
| Amgen INC. | $215.23 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $205.16 | 2023-2025 | Orgovyx, Gemtesa |
| Procept Biorobotics Corporation | $203.28 | 2022-2023 | Aquabeam Robotic System |
| Allergan, INC. | $186.75 | 2019-2021 | |
| Myovant Sciences INC. | $135.36 | 2021-2022 | |
| Urogen Pharma, INC. | $115.92 | 2021-2025 | Jelmyto |
| Boston Scientific Corporation | $101.86 | 2019-2025 | Spaceoar Vue System - 10ml |
| Histosonics, INC. | $90.33 | 2025 | |
| Edap Technomed INC | $87.00 | 2024 | |
| Accord Healthcare, INC. | $77.23 | 2022 | |
| Merck Sharp & Dohme LLC | $73.83 | 2021-2025 | Keytruda, Lynparza |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lepinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.